Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:35:53.359Z.
Calculation as of: 2026-10-06T13:35:53.359Z.
Quote observation: 2026-10-06T13:35:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.47B
Price/FCF Ratio
9.73
TTM Avg
9.98
3Y Avg
22.18
5Y Avg
99.17
Market Cap
$1.45B
Price/FCF Ratio
80.34
TTM Avg
258.29
3Y Avg
258.29
5Y Avg
172.61
Market Cap
$1.53B
Price/FCF Ratio
103.90
TTM Avg
59.64
3Y Avg
44.52
5Y Avg
43.50
Market Cap
$1.42B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.49B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 9.73 | 9.98 | 22.18 | 99.17 |
| GH Research PLC (GHRS)vs › | $1.51B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.45B | 80.34 | 258.29 | 258.29 | 172.61 |
| Innoviva, Inc. (INVA)vs › | $1.53B | 8.10 | 9.29 | 8.77 | 7.33 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.53B | 103.90 | 59.64 | 44.52 | 43.50 |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.58B | 25.67 | 16.96 | 29.77 | 40.80 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
